Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGT | O15294 | 8/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18965281 | 1.00 | OGT (0.76) | OGTALDH1A1MAPTHTTLMNA | |
| SCHEMBL4544718 | 0.86 | OGT (1.00) | OGTALDH1A1MAPTGAAPOLB | |
| SCHEMBL17407175 | 0.81 | OGT (0.66) | OGTALDH1A1MAPTHTTLMNA | |
| SCHEMBL17407172 | 0.81 | OGT (0.66) | OGTALDH1A1MAPTHTTLMNA | |
| SCHEMBL17407150 | 0.81 | OGT (0.67) | OGTALDH1A1MAPTHTTLMNA | |
| SCHEMBL17407177 | 0.81 | OGT (0.66) | OGTALDH1A1MAPTHTTLMNA | |
| SCHEMBL17407149 | 0.81 | OGT (0.67) | OGTALDH1A1MAPTHTTLMNA | |
| SCHEMBL17407176 | 0.81 | OGT (0.66) | OGTALDH1A1MAPTHTTLMNA | |
| SCHEMBL17407170 | 0.81 | OGT (0.70) | OGTALDH1A1MAPTHTTLMNA | |
| SCHEMBL17407171 | 0.81 | OGT (0.70) | OGTALDH1A1MAPTHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166558-A1 | O-GLCNAC TRANSFERASE (OGT) INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166558-A1 | O-GLCNAC TRANSFERASE (OGT) INHIBITORS AND USES THEREOF | OGA, OGT, CSGALNACT1 | OGT 2/4885ALDH1A1 995/4885MAPT 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.